Zullo A et al. |
A new highly effective short-term therapy schedule for Helicobacter pylori eradication. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10848654
|
Ikeda S et al. |
Evaluation of the cost-effectiveness of Helicobacter pylori eradication triple therapy vs. conventional therapy for ulcers in Japan. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11683692
|
Moayyedi P et al. |
The effectiveness of omeprazole, clarithromycin and tinidazole in eradicating Helicobacter pylori in a community screen and treat programme. Leeds Help Study Group. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10848655
|
Katelaris PH et al. |
Randomized trial of omeprazole and metronidazole with amoxycillin or clarithromycin for Helicobacter pylori eradication, in a region of high primary metronidazole resistance: the HERO study. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10848659
|
Ammon S et al. |
Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10848660
|
Leiper K et al. |
Open label trial of oral clarithromycin in active Crohn's disease. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10848665
|
Sharara AI et al. |
Letter: clarithromycin dose for H. pylori therapy remains unresolved--authors' reply. |
2015 |
Aliment. Pharmacol. Ther. |
pmid:26238584
|
Wheeldon TU et al. |
The importance of the level of metronidazole resistance for the success of Helicobacter pylori eradication. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15191514
|
Datta S et al. |
Most Helicobacter pylori strains of Kolkata in India are resistant to metronidazole but susceptible to other drugs commonly used for eradication and ulcer therapy. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15963080
|
Gisbert JP et al. |
7-day rescue therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15882246
|
Nista EC et al. |
Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15882245
|
Gisbert JP and Calvet X |
Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. |
2012 |
Aliment. Pharmacol. Ther. |
pmid:22129228
|
Lehmann FS et al. |
Effect of ornidazole and clarithromycin resistance on eradication of Helicobacter pylori in peptic ulcer disease. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10735923
|
Miwa H et al. |
Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients-a double-blind placebo-controlled study. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10735925
|
Malfertheiner P et al. |
Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12969088
|
Hassan C et al. |
Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12969091
|
Vakil N et al. |
Duplicate breath testing to confirm eradication of Helicobacter pylori: incremental benefit and cost in 419 patients. |
2008 |
Aliment. Pharmacol. Ther. |
pmid:18774949
|
Ahuja V et al. |
Lansoprazole and secnidazole with clarithromycin, amoxycillin or pefloxacin in the eradication of Helicobacter pylori in a developing country. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9678815
|
Grübel P and Cave DR |
Factors affecting solubility and penetration of clarithromycin through gastric mucus. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9678818
|
Malfertheiner P et al. |
Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11860399
|
Huang J and Hunt RH |
The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10383500
|
Miwa H et al. |
Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10383502
|
Ducóns JA et al. |
Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10383507
|
Vakil N et al. |
Seven-day therapy for Helicobacter pylori in the United States. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15225176
|
Wong BC et al. |
Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11736727
|
Hoffman JS et al. |
Efficacy of a 1-week regimen of ranitidine bismuth citrate in combination with metronidazole and clarithromycin for Helicobacter pylori eradication. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10215735
|
Gisbert JP et al. |
Helicobacter pylori eradication: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics for 1 week-a meta-analysis of efficacy. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10971230
|
Frevel M et al. |
Eradication of Helicobacter pylori with pantoprazole and two antibiotics: a comparison of two short-term regimens. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10971231
|
Bigard MA et al. |
One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9690730
|
Tam YH et al. |
Seven-day is more effective than 4-day ranitidine bismuth citrate-based triple therapy in eradication of Helicobacter pylori in children: a prospective randomized study. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16803605
|
Bardhan KD et al. |
Pantoprazole-based 10-day triple therapy is effective in Helicobacter pylori eradication. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9692693
|
Sengupta S et al. |
Effect of oral clarithromycin on gall-bladder motility in normal subjects and those with gall-stones. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16803607
|
Catalano F et al. |
Ranitidine bismuth citrate versus omeprazole triple therapy for the eradication of Helicobacter pylori and healing of duodenal ulcer. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9692702
|
Dobrilla G et al. |
Ranitidine bismuth citrate with either clarithromycin 1 g/day or 1.5 g/day is equally effective in the eradication of H. pylori and healing of duodenal ulcer. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9692703
|
Perri F et al. |
Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:14535875
|
Harris A |
H. pylori eradication by LAC. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9354216
|
Jung YS et al. |
Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. |
2017 |
Aliment. Pharmacol. Ther. |
pmid:28497487
|
Savarino V et al. |
A new 1-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus two antibiotics. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9305478
|
Yousfi MM et al. |
Metronidazole, ranitidine and clarithromycin combination for treatment of Helicobacter pylori infection (modified Bazzoli's triple therapy). |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8871452
|
Broutet N et al. |
Risk factors for failure of Helicobacter pylori therapy--results of an individual data analysis of 2751 patients. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12492738
|
Chi CH et al. |
Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of Helicobacter pylori. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12895220
|
Ott EA et al. |
Helicobacter pylori eradication does not cause reflux oesophagitis in functional dyspeptic patients: a randomized, investigator-blinded, placebo-controlled trial. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15882244
|
Weldon MJ et al. |
A seven-day Helicobacter pylori treatment regimen using clarithromycin, omeprazole and tripotassium dicitrato bismuthate. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8791951
|
Tursi A et al. |
Low-dose omeprazole plus clarithromycin and either tinidazole or amoxycillin for Helicobacter pylori infection. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8791952
|
Chen PY et al. |
Letter: levofloxacin resistance - a challenge for treatment of Helicobacter pylori infection. Authors' reply. |
2017 |
Aliment. Pharmacol. Ther. |
pmid:28074519
|
Gisbert JP and Pajares JM |
Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:12030945
|
Zamani M et al. |
Letter: levofloxacin resistance - a challenge for the treatment of Helicobacter pylori infection. |
2017 |
Aliment. Pharmacol. Ther. |
pmid:28074507
|
Laine L and Dhir V |
Helicobacter pylori eradication does not worsen quality of life related to reflux symptoms: a prospective trial. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:12030957
|
Vallve M et al. |
Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:12030958
|
McNulty CA et al. |
Is Helicobacter pylori antibiotic resistance surveillance needed and how can it be delivered? |
2012 |
Aliment. Pharmacol. Ther. |
pmid:22469191
|